Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT

Biomaterials

Volumn 34, Issue 32, 2013, Pages 7994-8001

  Chuang, Er Yuan ^a   Nguyen, Giang Thi Ha ^a   Su, Fang Yi ^a   Lin, Kun Ju ^b,c   Chen, Chiung Tong ^d   Mi, Fwu Long ^e   Yen, Tzu Chen ^c   Juang, Jyuhn Huarng ^c   Sung, Hsing Wen ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Glucoregulatory activity; Glucose utilization; Hyperinsulinemia; Postprandial hyperglycemia; Translational medicine

Indexed keywords

BLOOD GLUCOSE LEVEL; COMBINATION THERAPY; HYPERINSULINEMIA; ORAL GLUCOSE TOLERANCE TESTS; POSTPRANDIAL HYPERGLYCEMIA; TRANSLATIONAL MEDICINE; TYPE 2 DIABETES MELLITUS; TYPE 2 DIABETIC RATS;

AMINO ACIDS; BLOOD; GLUCOSE; NANOPARTICLES; PATIENT TREATMENT; RATS;

INSULIN;

CHITOSAN; EXENDIN 4; INSULIN; NANOPARTICLE; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PERMEABILIZATION; COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT;

BOVINAE; RATTUS;

EID: 84881029137     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.021     Document Type: Article

References (38)

1. Defronzo R.A. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
2. Mudaliar S., Edelman S.V. Insulin therapy in type 2 diabetes. Endocrin Metab Clin 2001, 30:935-982.
3. Aronoff S.L., Berkowitz K., Shreiner B., Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 2004, 17:183-190.
4. Peyrot M., Rubin R.R., Lauritzen T., Skovlund S.E., Snoek F.J., Matthews D.R., et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 2005, 28:2673-2679.
5. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
6. Derosa G., Sibilla S. Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 2007, 3:665-671.
7. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
8. Buse J.B., Bergenstal R.M., Glass L.C., Heilmann C.R., Lewis M.S., Kwan A.Y.M., et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
9. Zambanini A., Newson R.B., Maisey M., Feher M.D. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999, 46:239-246.
10. Carino G.P., Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999, 35:249-257.
11. Hamman J.H., Enslin G.M., Kotze A.F. Oral delivery of peptide drugs: barriers and developments. Biodrugs 2005, 19:165-177.
12. Sonaje K., Lin K.J., Wang J.J., Mi F.L., Chen C.T., Juang J.H., et al. Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv Funct Mater 2010, 20:3695-3700.
13. Sung H.W., Sonaje K., Liao Z.X., Hsu L.W., Chuang E.Y. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res 2012, 45:619-629.
14. Sonaje K., Chuang E.Y., Lin K.J., Yen T.C., Su F.Y., Tseng M.T., et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharmaceut 2012, 9:1271-1279.
15. Sonaje K., Lin Y.H., Juang J.H., Wey S.P., Chen C.T., Sung H.W. Invivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009, 30:2329-2339.
16. Nguyen H.N., Wey S.P., Juang J.H., Sonaje K., Ho Y.C., Chuang E.Y., et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion invivo. Biomaterials 2011, 32:2673-2682.
17. Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20:1822-1826.
18. Chuang E.Y., Lin K.J., Su F.Y., Mi F.L., Maiti B., Chen C.T., et al. Noninvasive imaging oral absorption of insulin delivered by nanoparticles and its stimulated glucose utilization in controlling postprandial hyperglycemia during OGTT indiabetic rats. JControl Release 2013, 10.1016/j.jconrel.2013.05.006.
19. Masiello P. Animal models of type 2 diabetes with reduced pancreatic beta-cell mass. Int J Biochem Cell Biol 2006, 38:873-893.
20. Su F.Y., Lin K.J., Sonaje K., Wey S.P., Yen T.C., Ho Y.C., et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 2012, 33:2801-2811.
21. Isherwood B., Timpson P., McGhee E.J., Anderson K.I., Canel M., Serrels A., et al. Live cell invitro and invivo imaging applications: accelerating drug discovery. Pharmaceutics 2011, 3:141-170.
22. Chen M.C., Wong H.S., Lin K.J., Chen H.L., Wey S.P., Sonaje K., et al. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 2009, 30:6629-6637.
23. Sonaje K., Lin K.J., Wey S.P., Lin C.K., Yeh T.H., Nguyen H.N., et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31:6849-6858.
24. Hara T., Inagaki K., Kosaka N., Morita T. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. JNucl Med 2000, 41:1507-1513.
25. Hellwig D., Graeter T.P., Ukena D., Groeschel A., Sybrecht G.W., Schaefers H.J., et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?. JNucl Med 2007, 48:1761-1766.
26. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004, 6:510-517.
27. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. JClin Endocrinol Metab 2003, 88:3082-3089.
28. Chae S.Y., Jin C.H., Shin H.J., Youn Y.S., Lee S., Lee K.C. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem 2008, 19:334-341.
29. Gao W., Jusko W.J. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. JPharmacol Exp Ther 2011, 336:881-890.
30. Franc B.L., Acton P.D., Mari C., Hasegawa B.H. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. JNucl Med 2008, 49:1651-1663.
31. Nauck M.A., Meier J.J. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?. Nat Rev Endocrinol 2011, 7:193-195.
32. Kapoor V., McCook B.M., Torok F.S. An introduction to PET-CT imaging. Radiographics 2004, 24:523-543.
33. Bryant N.J., Govers R., James D.E. Regulated transport of the glucose transporter glut4. Nat Rev Mol Cell Biol 2002, 3:267-277.
34. Ho K.C., Lin G.G., Wang J.J., Lai C.H., Chang C.J., Yen T.C. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol 2009, 36:200-208.
35. Orci L., Unger R.H. Functional subdivision of islets of Langerhans and possible role of D cells. Lancet 1975, 2:1243-1244.
36. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
37. Knop F.K., Vilsboll T., Madsbad S., Holst J.J., Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007, 50:797-805.
38. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.